Aytu BioPharma Inc. Common Stock (AYTU)
Stock · NASDAQ · Health Care
$2.01as of 10/16/2026
Price chart
Active signals
AYTU Signal Track Record
How signals performed across all stocks →What AYTU's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 52 | -2.9% | 40% | September 30, 2026 |
| Bollinger Band Breakdown | 25 | +10.3% | 68% | September 9, 2026 |
| Bollinger Band Breakout | 18 | -6.7% | 28% | August 5, 2026 |
| 200-Day Moving Average TouchActive now | 6 | -8.6% | 17% | August 21, 2026 |
| Any 20-session window (baseline) | -4.3% | 38% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About AYTU
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indi…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 75
- Website
- aytubio.com/
Fundamentals
- 1-day range
- $1.96$2.14
- Market cap
- $25.01M
- P/E (trailing)
- —
- P/E (forward)
- 13.16
- EPS (trailing)
- $-1.49
- Dividend yield
- —
- Beta
- 0.18
- Avg. volume
- 34.8K
- Dividend pay date
- December 9, 2020
How Aytu BioPharma Inc. Common Stock Makes Money
Where the revenue actually goes — FY2026 annual results
Source: 10-K filed Sep 22, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Aytu BioPharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- AYTUAytu BioPharma Inc. Common Stock$2.04▲ 1.49%Market cap $25.01MP/E —$1.8$3.07
- ATNMActinium Pharmaceuticals Inc. (Delaware) Common Stock$1.13▲ 6.60%Market cap $24.69MP/E 2.95$0.7351$1.74
- LGVNLongeveron Inc. Class A Common Stock$1.39▼ 7.33%Market cap $24.44MP/E —$1.69$12.3
- TXMDTherapeuticsMD Inc. Common Stock$1.9▼ 1.55%Market cap $24.19MP/E 135.01$1.03$2.95
- IGCIGC Pharma Inc. Common Stock$0.25▲ 0.00%Market cap $23.94MP/E —$0.235$0.4508
- TVRDTvardi Therapeutics Inc. Common Stock$1.01▼ 5.61%Market cap $23.02MP/E —$0.93$7.23
- ABVCABVC BioPharma Inc. Common Stock$0.918▼ 1.61%Market cap $27.09MP/E —$0.7069$3.07
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AYTU Aytu BioPharma Inc. Common Stock | $25.01M | — | $2.04 | ▲ 1.49% | $1.8$3.07 |
| ATNM Actinium Pharmaceuticals Inc. (Delaware) Common Stock | $24.69M | 2.95 | $1.13 | ▲ 6.60% | $0.7351$1.74 |
| LGVN Longeveron Inc. Class A Common Stock | $24.44M | — | $1.39 | ▼ 7.33% | $1.69$12.3 |
| TXMD TherapeuticsMD Inc. Common Stock | $24.19M | 135.01 | $1.9 | ▼ 1.55% | $1.03$2.95 |
| IGC IGC Pharma Inc. Common Stock | $23.94M | — | $0.25 | ▲ 0.00% | $0.235$0.4508 |
| TVRD Tvardi Therapeutics Inc. Common Stock | $23.02M | — | $1.01 | ▼ 5.61% | $0.93$7.23 |
| ABVC ABVC BioPharma Inc. Common Stock | $27.09M | — | $0.918 | ▼ 1.61% | $0.7069$3.07 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy?Yahoo · 10/7/2026
- Microsoft To Rally Around 20%? Here Are 10 Top Analyst Forecasts For WednesdayBenzinga · 9/30/2026
- Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $15Benzinga · 9/30/2026
- Aytu BioPharma, Inc. Q4 2026 Earnings Call SummaryYahoo · 9/23/2026
- Aytu BioPharma Inc (AYTU) (Q4 2026) Earnings Call Highlights: EXXUA Launch Accelerates as ...Yahoo · 9/23/2026
- Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue EstimatesYahoo · 9/22/2026
- Aytu BioPharma Inc. (NASDAQ:AYTU) Shares Jump 125% on Q4 Beat and Strong EXXUA LaunchChartMill · 9/22/2026
- Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial ResultsYahoo · 9/22/2026
Insider Activity
Insider Actions →- Joshua R. Disbrow · July 28, 2026 · Grant30.0K
- Greg Pyszczymuka · July 28, 2026 · Grant20.0K
- Jarrett Disbrow · July 28, 2026 · Grant15.0K
- Ryan J. Selhorn · July 28, 2026 · Grant25.0K
- Abhinav Jain · July 28, 2026 · Grant10.0K
- Carl Dockery · July 28, 2026 · Grant10.0K
- John Donofrio Jr. · July 28, 2026 · Grant10.0K
- Vivian H. Liu · July 28, 2026 · Grant10.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 3.86M
- Total value held
- $10.10M
- Institutional holders
- 34
- Unknown1.09M
- Unknown792.3K
- Unknown619.6K
- Unknown353.1K
- Unknown261.1K
- Unknown145.0K
- Unknown122.0K
- Unknown93.7K
- Unknown92.9K
- Unknown92.6K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Ascendiant Keeps Positive Outlook on Aytu, Raises Target to $15
Ascendiant Capital keeps a bullish view and raised its target to $15. The target sits well above the 52‑week high of $3.06, indicating a potential upside. The stock is currently trading near its support level of $2.17 and has an RSI of 45.6, suggesting neither overbought nor oversold conditions.
Ascendiant Keeps Positive Outlook on Aytu, Raises Target to $15. Ascendiant Capital keeps a bullish view and raised its target to $15. The target sits well above the 52‑week high of $3.06, indicating a potential upside. The stock is currently trading near its support level of $2.17 and has an RSI of 45.6, suggesting neither overbought nor oversold conditions.